LOGO
LOGO

Pacira BioSciences To Present Immunogenicity Data For PCRX-201 At ASGCT 2025

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

Pacira BioSciences, Inc. (PCRX) will present new findings from its Phase 1 clinical trial of gene therapy candidate PCRX-201 in osteoarthritis of the knee at the 28th Annual Meeting of the American Society of Gene and Cell Therapy or ASGCT on Thursday, May 15, 2025.

The presentation will focus on the clinical immunogenicity of the therapy and its implications for optimizing dosing strategy in knee osteoarthritis.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update - Jun 01 - Jun 05, 2026

June 05, 2026 16:18 ET
A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.

Latest Updates on COVID-19